Lode H
Krankenhaus Zehlendorf, Lehrkrankenhaus der FU Berlin, Germany.
Infection. 1991;19 Suppl 1:S72-3. doi: 10.1007/BF01644740.
The evaluation of the efficacy and possible intolerance of an antibacterial chemotherapy is based on the exact analysis of patient specific signs and symptoms, pathogenetic factors of the specific bacteria and parameters of the specific substance. One has to differentiate between usefulness of the antibiotics (effect) and the possible risks for the patient as well as for the physician involved. Today the legal regulations have become so strict for treatment with new substances in phase II to III studies that in most of the new chemotherapeutic substances the relationship between efficacy and possible intolerance reactions may be judged as optimal for both the patient and the physician. Our own experiences have shown that patients involved in studies with well designed protocols are better controlled and in most instances also better treated than patients treated outside such protocols.
抗菌化疗疗效及可能出现的不耐受情况的评估,基于对患者特定体征和症状、特定细菌的致病因素以及特定物质参数的精确分析。必须区分抗生素的效用(效果)以及对患者和相关医生可能存在的风险。如今,在II期至III期研究中使用新物质进行治疗的法律法规变得如此严格,以至于在大多数新型化疗物质中,疗效与可能的不耐受反应之间的关系对患者和医生而言都可被判定为最佳。我们自己的经验表明,参与精心设计方案研究的患者比未参与此类方案治疗的患者得到了更好的控制,而且在大多数情况下治疗效果也更好。